ClinicalTrials.gg

Program

TTAX-03

Also written as “TTAX03”, “TTAX03 10mg” and “TTAX03 25mg”.

Its studies are mostly in Dry Eye Syndromes · Osteoarthritis, Knee · Arthralgia, led by BioTissue.

Furthest: phase 2, since Sep 22, 20213 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioTissue30 open or runningphase 2since Sep 22, 2021Sep 22, 2021none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 22, 2021First study: phase 2 study in Osteoarthritis, KneeFirst studyNCT05079035 · 90 enrolled · United States
  2. Nov 6, 2023Phase 1 study in Facet Joint PainNCT06236308
  3. Jan 13, 2025Phase 2 study in Dry Eye SyndromesNCT06780306 · 74 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06780306Dry Eye Syndromes · United States2CompletedJan 30, 202674
NCT06236308Facet Joint Pain1WithdrawnJan 31, 20250
NCT05079035Osteoarthritis, Knee · United States2CompletedMar 7, 202590

How it is read

Names in the registry

  • “TTAX03”, 2 entries
  • “TTAX03 10mg”, 1 entry
  • “TTAX03 25mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.